Japan Lifeline (7575) Q3 2025 earnings summary

Executive summary

• 9M FY2025 net sales rose 11.8% to ¥42,811M, operating profit increased 17.2% to ¥9,906M, and net profit grew 14.5% to ¥7,071M; all reached nine-month records.

• Core products and strategic growth segments drove expansion, offsetting reimbursement price reductions; results included ¥350M of one-time SG&A expenses.

• Full-year earnings and dividend forecasts were raised on January 31, 2025.

Financial highlights

• Q3 net sales were ¥14,825M (+12.6% YoY), operating profit ¥3,646M (+22.5%), and net profit ¥2,635M (+23.2%).

• 9M EPS was ¥99.37 (+23.1% YoY); operating margin rose 100 bps to 23.1%, while gross margin declined 30 bps to 60.5%.

• Excluding non-recurring expenses, operating profit growth was 21.4% and net profit growth was 20.1%; prior-year SG&A included a ¥148M reversal that did not recur.

• June reimbursement revisions reduced 9M revenue by ¥700M and gross profit by ¥360M; lower inventory write-downs added ¥150M to gross profit.

• Revenue increased ¥4,508M YoY: established segments added ¥3,806M and strategic growth segments ¥934M, partly offset by ¥231M from discontinued businesses.

Outlook and guidance

• FY2025 guidance increased to net sales ¥56,800M, operating profit ¥12,600M, and net profit ¥9,200M.

• Revised EPS forecast is ¥129.78, up from ¥113.58; dividend forecast rose to ¥53 per share, consistent with a 40% payout-ratio policy.

• Q4 revenue is expected to decline sequentially as the quarter has five fewer business days, reducing revenue by over ¥1B; revenue per business day was trending upward at ¥220M–¥245M.

• Q4 SG&A is expected to be ¥400M above prior quarters, including over ¥500M in R&D spending; operating margin forecast is 19.3%.